Pyruvate and ME/POTS

Fluge, Mella et al. have shown that ME is associated with defective oxidative metabolism - most likely involving impaired pyruvate dehydrogenase function (1).

Expression of the protein mitochondrial pyruvate carrier 2 (MCC2) has been found downregulated in ME (2)

The gene similar to pyruvate kinase-isozymes M1/M2 (PKM2) has been found epigenetic changed (hypermethylated) in ME (3).

Immunoreactive proteins against IgGs from POTS patients (4, 5):

• ODPB, pyruvate dehydrogenase E1 component subunit beta.
• KPYM, pyruvate kinase isoenzyme M1.
• PDHX, pyruvate dehydrogenase protein X component.
• PKM2, pyruvate kinase isozymes M1/M2

References:

1.  Fluge et al: Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy / chronic fatigue syndrome. JCI Insight. 2016; 1(21):e89376. Doi 10.1172/jci.insight.89276
2. Ciregia et al.
   Translational Psychiatry (2016), 6, e904
   doi:10.1038/tp.2016.184
3. Vega et al. DNA methylation Modifications associated with CFS. Plos One, aug 2014, vol 9, Issue 8, e104757
4. Wang et al: Autoimmunoreactive IgGs from patients with POTS. Prot. Clin. Appl. 2012, 6, 1-11.
5. Wang et al: Autoimmunoreactive IgGs against cardiac lipid raft-associated proteins in patients with POTS. doi: 10.1016/j.trsl.2013.03.002